← Back to headlines
Novo Nordisk Heart Drug Fails Late-Stage Trial
Novo Nordisk's NVO stock plummeted after its heart drug failed a late-stage clinical trial, impacting investor confidence.
31 Jul, 19:00 — 31 Jul, 19:00
Sources
Showing 1 of 1 sources
